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Summary To evaluate the prognostic significance of immunohistochemically detected p53 and Bcl-2 proteins in colorectal cancer, tissue
sections from 238 paraffin-embedded colorectal carcinomas were immunostained for p53 (MAb DO-7 and CM-1 antiserum) and Bcl-2 (MAb
Bcl-2:124). Staining patterns were assessed semiquantitatively and correlated with each other and with sex, age, tumour site, Dukes'
classification, tumour differentiation, mucinous characteristics, lymphocyte and eosinophilic granulocyte infiltration, and patient survival. In our
series, 35% of carcinomas showed no nuclear staining and 34% (DO-7) to 40% (CM-1) showed staining in over 30% of tumour cell nuclei. A
majority of carcinomas that had been immunostained with CM-1 showed cytoplasmic staining, but this was not observed with DO-7. With
respect to Bcl-2, 51% of tumours were completely negative, 32% displayed weak and 15% moderate staining; only 3% showed strong
positive staining. No evidence was found for reciprocity between Bcl-2 expression and nuclear p53 accumulation. From 13 cases containing
tumour-associated adenoma, four were Bcl-2 negative in premalignant and malignant cells, in another four cases these cells showed similar
staining intensities and in the remaining cases only the malignant colorectal cells were Bcl-2 negative. Therefore, our data indicate that Bcl-2
is dispensable in the progression towards carcinoma. Except for an association between nuclear p53 accumulation and mucinous tumours
(P = 0.01), no significant correlation was found between the clinicopathological parameters mentioned above and immunostaining pattern of
(nuclear or cytoplasmic) p53 or Bcl-2.
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At present, prognostication for colorectal cancer is based mainly
on tumour stage, but, because marked differences in clinical
outcome occur within each stage, there is an obvious need for
better prognostic markers. Ideally, these markers should predict
the chance that the tumour has disseminated at the time ofprimary
surgery, thereby facilitating selection ofsubgroups ofpatients who
might benefit from adjuvant chemotherapy and radiation therapy.
For this purpose we selected a population of patients who under-
went a curative resection without adjuvant chemotherapy and for
whom post-operative follow-up was available.
In normal colorectal mucosa there exists a stringently controlled
balance between cell proliferation and cell death, and it has been
hypothesized that a reduced capacity to undergo apoptotic cell
death could be an important step in the development of neoplasia.
(Bedi et al, 1995). Both the product ofthe tumour suppressor gene
p53 and the products ofthe bcl-2 gene family are involved in regu-
lation of cell proliferation and apoptosis, and alterations in these
genes are related to oncogenesis and disease progression.
Loss ofp53 function has been strongly linked to development of
malignancy (Hollstein et al, 1991) - about 70% of colorectal
cancers were shown to bearp53 mutations and a similar percentage
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showed a reduction to homozygosity at the p53 locus (Baker et al,
1990). These mutations were found to arise predominantly during
the conversion of benign adenoma to invasive adenocarcinoma,
and the highest percentage was found in late-stage tumours (Fearon
and Vogelstein, 1990; Kikuchi-Yanoshita et al, 1992; Kaklamanis
et al, 1993). Deletions ofthe short arm ofchromosome 17p, which
harbours the p53 gene, and point mutations within the p53 gene (as
detected by sequence analysis) were found to be associated with
vascular invasion (lino et al, 1994), distant metastases (Kern et al,
1989; Ookawa et al, 1993; Kastrinakis et al, 1995) and shorter
survival (Laurent-Puig et al, 1992; Offerhaus et al, 1992; Hamelin
et al, 1994; Pricolo et al, 1996).
Within unperturbed cells, expression of wild-type (wt) p53
protein is generally below detection limits of immunohistochem-
istry (IHC). Stabilization of p53 protein (leading to accumulation
in the nuclei) occurs after an appropriate stimulus (e.g. DNA
damage), but also as a result ofloss offunction secondary to muta-
tion (Blagosklonny, 1997).
bcl-2 is one member of a gene family, products of which are
involved in either inhibition (e.g. Bcl-2, Bcl-XL) or promotion of
cell death (e.g. Bax, Bak). In colorectal tissues, Bcl-2 is highly
expressed at the base of crypts (Hockenbery et al, 1991; Bronner et
al, 1995; Merrit et al, 1995). The first studies on immunohistochem-
ical detection ofBcl-2 in neoplasms ofthe colorectal tract suggested
a high expression both in adenomas and carcinomas (Hague et al,
1994; Bronner et al, 1995), but more recent studies indicated a
significantly lower proportion of carcinomas to be Bcl-2 positive
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Table 1 bcl-2 and p53 expression and clinicopathological characteristics
Clinicopathological variable bcl-2 p53
n Moderate + high Stat n High expression, Stat
expression (%) >30% pos nuclei (%)
Sex
Male 113 17 NS 128 40 NS
Female 96 19 110 41
Age
050 years 23 17 NS 25 32 NS
>50 years 186 18 213 41
Site
Coecum-transverse 54 13 NS 58 33 NS
colon
Splenic flexure-descending 33 9 38 34
colon
Sigmoid-rectum 122 22 142 45
Differentiation
Poor 117 14 NS 130 41 NS
Moderate 58 22 67 40
Good 34 24 41 39
Mucinous 57 18 NS 68 28 0.01
Non-mucinous 152 18 170 45
Lymphocytic infiltration
Low 75 16 NS 91 41 NS
Intermediate 94 22 105 41
High 40 10 42 38
Eosinophilic infiltration
Low 126 18 NS 141 44 NS
Intermediate 46 15 54 41
High 37 21 43 28
Dukes' stage
A/B1 62 19 NS 66 33 NS
B2 89 17 104 42
C1+2 58 17 68 44
Table 2 Expression of Bcl-2 in colorectal carcinomas
Si F Bcl-2 score Frequency Percentage
0 2a 0 106 50.7
1 Qand 1 1 37 17.7
1 2 2 29 13.9
2 0 and 1 3 29 13.9
2 2 4 2 1.0
3 0 and 1 5 5 2.4
3 2 6 1 0.5
Missing 29
Total 238 100.0
SI, staining intensity, range of scores 0-3; F, fraction of positive tumour cells,
fraction of cells in each category: 0-25% = 0, 25-75% = 1, 75-100% = 2.
Tumours were grouped into separate categories, not by addition or
multiplication of the two scores, but by classifying them according to the
fraction of cells showing the most intense staining. Tumours that had the same
staining intensity (SI), but also contained a significant number of tumour cells
with less intense staining (score F = 0 or F = 1) were grouped together. This
scoring system resulted in Bcl-2 scores ranging from 0 to 6. al00% negative.
(Bosari etal, 1995; Baretton etal, 1996; Flohil et al, 1996; Watson et
al, 1996; Ward et al, 1997). With respect to the prognostic signifi-
cance of Bcl-2 staining in colorectal carcinomas, data were not
conclusive (Bosari et al, 1995; Ofner et al, 1995; Baretton et al,
1996). Moreover, whereas in adenomas an inverse relationship was
found between Bcl-2 expression and p53 accumulation, this could
not be confirmed in carcinomas (Sinicrope et al, 1995; Baretton et
al, 1996). However, adual stainingtechnique forbothBcl-2 andp53
suggested reciprocity of expression within individual tumours
(Watson et al, 1996).
In the present study we evaluated IHC ofboth p53 and Bcl-2 in
a series of 238 paraffin-embedded colorectal carcinomas from
patients that had a median follow-up of 40 months. We used the
monoclonal antibody (MAb) D07 and the polyclonal antiserum
CM-1 (Midgley et al, 1992) for p53 and the MAb Bcl-2:124
(Pezzella et al, 1990) for Bcl-2, analysing staining results as previ-
ously reported (Baas et al, 1994; Van Slooten et al, 1996). Ourdata
clearly demonstrate that IHC with these antibodies does not




From January 1980 until December 1992, 855 consecutive patients
with colorectal cancer were registered at the Leiden University
Hospital. Of these, 266 patients underwent curative resection for
colorectal adenocarcinoma and had a post-operative follow-up. A
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resection was considered curative when no tumour was left behind
and the patient was alive 30 days after surgery, with no evidence of
disease. These patients did not receive adjuvant chemotherapy and
were followed until January 1994 or until death.
For the present study, paraffin-embedded tissue samples from
238 patients were analysed (in 20 cases tissue blocks were not
available and in eight cases a double tumour was present). The
pathological staging was determined using the Astler-Coller
modification of Dukes' classification (Astler et al, 1954). In addi-
tion, presence of mucinous characteristics was assessed as well as
the amount of lymphocytic infiltration and eosinophilic granulo-
cyte infiltration (Jass et al, 1992). Patient and tumour characteris-
tics are listed in Table 1.
Immunohistochemistry
Sections (5 ,um) were deparaffinized in xylene. Endogenous
peroxidase was blocked by 0.3% hydrogen peroxide-methanol
for 20 min. After immersing the sections in alcohol they were
rehydrated. Antigen retrieval was performed by heating the
sections at 100°C in 10 mm citrate buffer (pH 6.0) for 10min.
After a short rinse in phosphate-buffered saline (PBS), sections
were incubated overnight at room temperature with antibodies
either to p53 (clone DO-7 mouse antihuman MAb, 1:1000; CM-l
rabbit polyclonal antibody, 1:3000, Novocastra Laboratories,
Newcastle upon Tyne, UK) or to Bcl-2 (clone 124 mouse anti-
human MAb, 1:200, Boehringer Mannheim, Mannheim,
Germany). After several washing steps in PBS, sections were
incubated for 30 min with labelled second-step MAbs diluted
1:200 in PBS. For DO-7 and Bcl-2:124 we used biotinylated
rabbit-anti-mouse MAbs (Dakopatts, Glostrup, Denmark); for
CM-1 we used biotinylated donkey anti-rabbit anti-serum
(Amersham, Cleveland, OH, USA). PBS washings were followed
by incubation for 1 h with a complex of biotinylated horse radish
peroxidase and streptavidin (Dakopatts), diluted 1:100 in PBS.
Staining was developed in PBS containing 0.05% 3,3-diaminoben-
zidine tetrahydrochloride and 0.02% hydrogen peroxide. Sections
were counterstained with haematoxylin, dehydrated with ethanol,
cleared in xylene and mounted with malinol under a coverslip.
For p53 staining, a tumour with nuclear p53 accumulation
served as apositive control. ForBcl-2 staining infiltrating lympho-
cytes were used as an internal positive control because it has been
found that this cell population invariably contained strongly
stained cells. In 29 tumours, no positive lymphocytes could be
detected and these tumours were therefore not included in the
Bcl-2 analysis.
Analysis staining patterns
Nuclear staining of p53 was scored semiquantitatively by two
independent observers and expressed percentage of positive
tumour cells. Tumours were assigned to one of three categories:
high expression, more than 30% of cancer cells stained; low
expression, 1-30% ofcancer cells stained; and no expression, 0%
cancer cells stained (Baas et al, 1994). Apart from nuclear
staining, we also estimated the presence of cytoplasmic staining;
staining intensity (SI) was scored as low, intermediate or high.
Staining of Bcl-2 was evaluated simultaneously by two
observers. Table 2 defines the full scoring system for the level of
Bcl-2 staining. SI was scored negative (0), weakly (1), moderately
(2) or strongly positive (3). Marked intratumour heterogeneity for
SI was observed in one-third of cases, but only a few 'heteroge-
neous' tumours contained a fraction oftumourcells virtually nega-
tive for Bcl-2. For that reason it was decided not to count the
number of Bcl-2-'positive' tumour cells. Instead, the fraction of
cells showing the highest SI was estimated and assigned to the
categories 0-25% (0), 25-75% (1) or 75-100% (2) (Van Slooten
et al, 1996).
Statistics
The relationship between the various clinicopathological parame-
ters and p53 or Bcl-2 staining was evaluated using the chi-square
test for two group comparisons. Overall survival curves were
constructed according to the method of Kaplan and Meier.
Survival curves were compared using the log-rank test.
RESULTS
p53 expression
Among the 238 adenocarcinomas studied, 77 (36.1%) were
completely negative after immunostaining with DO-7, 56 (23.5%)
showed < 30% positive tumour cell nuclei and 96 (40.3%) showed
> 30% positive nuclei. In sporadic cases we observed faint cyto-
plasmic p53 staining. With CM-I immunostaining, 17 adenocarci-
nomas (7.1%) were completely devoid ofp53 expression, whereas
only 12 tumours (5.0%) showed staining confined to the nucleus.
Negative nuclei were observed in 83 cases (34.9%), < 30% posi-
tive nuclei in 75 cases (31.5%) and >30% positive nuclei in 80
cases (33.6%). Staining intensity (SI) ofcytoplasmic staining was
scored as low (42.4%), intermediate (38.7%) orhigh (6.7%). Only
one tumour with >30% positive nuclei showed a high cytoplasmic
SI. Both with DO-7 and CM-1, normal colonic mucosa was
completely negative in all cases evaluated.
BCL-2 EXPRESSION
As shown in Table 2, tumours were grouped into separate cate-
gories according to the fraction of cells showing the most intense
staining; tumours with a similar SI in at least half of the tumour
cell population were grouped together. Resulting categories were
designated 0-6. From 219 evaluable tumours 50.7% was
completely negative (0), 31.1% weakly positive (score 1+2),
14.9% moderately positive (score 3+4) and 2.9% strongly positive
(score 5+6). Many tumours showed homogeneously weak staining
ofthe carcinoma cells.
In 13 cases we found adenomatous areas at the mucosal edge of
the neoplasm: in four cases Bcl-2 expression in the non-malignant
cells was similar to that in their malignant counterparts, in five
cases Bcl-2 was present in the non-malignant cells, but absent in
the carcinoma, and in four cases both cell types were negative.
Correlation with clinicopathological parameters,
disease-free interval and survival
No correlation was found between Bcl-2 and p53 expression. The
result was no different when the more detailed categorization was
used for Bcl-2 or when nuclear p53 expression was analysed
without the moderately stained group (1-30% positive tumour cell
nuclei) orwith different cut-offpoints between staining categories.
Non-mucinous tumours showed more nuclear p53 overexpression
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Figure 1 Kaplan-Meier curves of the 209 patients with colorectal
carcinoma with regard to high and low Bcl-2 immunoreactivity
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Figure 2 Kaplan-Meier curves of the 238 patients with colorectal
carcinoma with regard to high or low vs no nuclear p53 protein accumulation
(MAb DO-7)
than mucinous tumours (MAb DO-7; P = 0.01). With this single
exception, neitherp53 nor Bcl-2 were related to any ofthe clinico-
pathological parameters (Table 1) and no significant difference in
survival was detected between patients with tumour tissue
displaying moderate to high vs low or no expression (Figures 1
and 2). Similar results were found for disease-free survival (data
not shown). The more detailed categorization of p53 or Bcl-2
staining did not change the results and no significant correlation
with disease-free or overall survival was detected for subgroups
based on combined p53/Bcl-2 score (p53+/Bcl-2+; p53+/Bcl-2-;
p53-/Bcl-2+; p53-/Bcl-2-; not shown).
DISCUSSION
This study shows that IHC for p53 and Bcl-2 does not predict
survival in colorectal cancer. This is in line with most ofthe litera-
ture. Only approximately one-third of all studies on the prognostic
value ofIHC ofp53 in colorectal cancer indicated its potential rele-
vance, a situation similar to that for IHC of Bcl-2 (Manne et al,
1997; Tollenaar, 1997). For instance, Manne et al (1997) recently
concluded from a series of 134 patients that both parameters inde-
pendently give relevant information on prognosis. Data from their
study confirm our own conclusion that IHC ofp53 does not seem to
correlate with clinicopathological parameters, except for the more
prominent presence of p53 in non-mucinous tumours; the latter
phenomenon was also noticed by other investigators (Campo et al,
1991; Hanski et al, 1992; Mulder et al, 1995) and adds to the likeli-
hood that mucus-producing tumours (being approximately 10-
15% of colorectal carcinomas) constitute a subset of colorectal
neoplasms with a different biology. But for both p53 and Bcl-2 the
conclusions differ with respect to patient survival, and it is difficult
to establish whether this results from differences in materials and
methods or from differences in patient- (and tumour)-related char-
acteristics. It might be relevant in this context that the patient
groups differed in age distribution, ethnic (i.e. genetic) background,
ratio ofleft- and right-sided tumours, presence ofdistant metastases
and whether or not adjuvant chemotherapy had been given.
Technical differences are seen in the type of antibodies and
antigen retrieval methods used as well as the percentage of p53-
positive cells used as cut-off point. Home et al (1996) recently
concluded from a panel of MAbs used on breast cancers that
pAbi801 and DO-7 are among the most effective antibodies for
IHC in routinely processed material. A similar study on colon
cancers revealed that staining with DO-7 after an antigen retrieval
method for paraffin sections was the most sensitive and specific
procedure (Baas et al, 1994). It is therefore remarkable that Manne
et al (1997), who used BP53-12-1 MAb after having established
that it gave similar results as pAbI801, reported that the above
antigen retrieval procedure abolished the relationship found
between p53 positivity and patient survival.
The polyclonal antiserum CM-I was reported to recognize both
mutant and wt-p53 on formalin-fixed material, and its use resulted
in both nuclear and cytoplasmic staining patterns (Midgley et al,
1992). In colorectal cancers, one study found nuclear CM-1
staining to be correlated with unfavourable clinical outcome
(Starzynska et al, 1992), but the follow-up period was short and
studies with longer follow-ups did not confirm this result (Sun
et al, 1992; Bosari et al, 1994; Mulder et al, 1995). Two reports
described the presence of marked cytoplasmic staining and
provided data suggesting that, whereas nuclear staining was not an
independent prognostic factor, cytoplasmic staining was highly
significantly associated with poor survival (Sun et al, 1992; Bosari
et al, 1994) However, this remarkable finding was not confirmed
by the present study.
Our data on Bcl-2 positivity are in line with published results
from relatively large patient series (Bosari et al, 1995; Ofner et al,
1995; Manne et al, 1997), showing no staining (except in infil-
trating lymphocytes) in about half of the tumours and strong
staining in a small subpopulation. We were not able to detect a
significant correlation between Bcl-2 expression and any of the
clinicopathological parameters evaluated, confirming data
obtained by Bosari et al (1995). Reported correlations include
tumour differentiation (Watson et al, 1996; Schneider et al, 1997),
lymphocyte infiltration and tumour size (Ofner et al, 1995), and
factors such as bowel wall and regional lymph node invasion and
presence of distant metastases (Manne et al, 1997). It was also
reported that Bcl-2-negative tumours tend to have higher apoptotic
indices (Baretton et al, 1996). But, as with p53, the literature is far
from equivocal on this subject.
In multivariate analysis, two research groups found Bcl-2 to be
an independent prognostic parameter with Dukes' classification or
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TNM as stratification factor (Offner et al, 1995; Manne et al,
1997), but others could not confirm this independence (Baretton et
al, 1996) and neither we nor Bosari et al (1993) could find any
correlation with a better clinical course. Moreover, using a MAb
different from that used in the above studies, Schneider et al
(1997) concluded Bcl-2 expression not to be associated with
survival or response to 5-fluorouracil-based chemotherapy.
Based on observed abnormal Bcl-2 immunoreactivity in the
earliest precursor dysplastic lesions and in contiguous non-
dysplastic epithelium, it has been proposed that Bcl-2 alterations
may occur very early in the sequence of events leading to gastro-
intestinal neoplasia (Bronner et al, 1995). Within normal mucosal
tissue adjacent to the carcinomas, we detected Bcl-2 over-
expression in basal and middle parts of the crypts - the more
differentiated surface epithelial cells were invariably negative.
Adenomatous areas showed either a similar staining pattern to the
carcinoma cells or a higher expression. Because a majority of
studies reported a higher frequency of Bcl-2-positive adenomas
compared with carcinomas, this would suggest that, although
many adenomas are derived from cells expressing relatively high
levels of Bcl-2, during progression towards overt carcinoma the
expansion ofcell clones with lower (or even no) expression ofBcl-
2 is strongly favoured. Moreover, it has been reported that colon
carcinomas that have no adenomatous elements in their vicinity
('de novo' carcinomas) tend to have even lower Bcl-2 expression
than 'ex-adenoma' carcinomas (Mueller et al, 1996).
Using a dual-staining technique, Watson et al (1996) noticed in
both adenomas and carcinomas reciprocity ofexpression of Bcl-2
and p53, and conjectured that accumulation of mutant p53 could
possibly silence the bcl-2 gene. However, other investigators
found reciprocity in adenomas, but not in carcinomas (Sinicrope et
al, 1995; Baretton et al, 1996) and, although we and others have
found a strong reciprocity ofBcl-2 and p53 in breast cancers (Van
Slooten et al, 1996), this reciprocity was virtually absent in the
present series. Also, Mosnier et al (1996) recently concluded that
in colorectal cancers deregulation of bcl-2 is probably not depen-
dent on p53 gene mutations.
A more likely explanation for loss of Bcl-2 is based on the
increasing evidence that Bcl-2 not only reduces apoptosis, but also
affects the cell cycle machinery (Watson et al, 1996). We and
others noticed that in breast cancers a strong inverse correlation
exists between Bcl-2 expression and proliferative activity (Van
Slooten et al, 1996) and Pietenpol et al (1994) described that in
several tumour cells lines (including colorectal cancer cells) over-
expression of Bcl-2 resulted in severe growth inhibition. More
recently, a number of reports have provided evidence that Bcl-2
can inhibit the transition of cells from a resting to a cycling phase
and stimulate the reverse condition (Mazel et al, 1996; Huang et al,
1997). However, it is not clear yet to what extent the loss of
apoptosis-inhibiting inhibiting function of Bcl-2 is compensated
by modulation of other factors involved in apoptosis regulation -
including the pro-apoptotic members of the Bcl-2 family
(Krajewska et al, 1996; Rampino et al, 1997).
Our results demonstrate that, even in a carefully selected series
of patients who underwent curative surgery without adjuvant
chemotherapy, p53 and Bcl-2 used as immunohistochemical
markers do not seem to have the potential to improve individually
tailored prognostication, and therefore we have little reason to
share the optimism expressed by some other investigators. The
only way to establish whether this discrepancy in findings is
merely based on technical aspects would be to exchange the
paraffin-embedded tumour material between the different research
groups. It might well be possible, however, that various tumour-
related factors may profoundly affect the impact ofp53 and Bcl-2
immunostaining patterns on prognosis and that more information
about these factors is needed to identify reliably relevant subtypes
ofcolorectal cancer.
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